secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-09-09T13:01:06+00:00
Accession:  0001193805-26-001196
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic holds RMS R&D Day webinar; presentation details not in filing
---------------------------------------------------------------------

- Immunic hosted RMS R&D Day webinar Sept 9, 2026, 11:00-12:30 ET via video conference.
- Presentation content not included in filing text; no specific clinical data or milestones disclosed in body.
- Forward-looking statements cite vidofludimus calcium and potential confirmatory phase 3 trial in progressive MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526001196/0001193805-26-001196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526001196/e665768_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-001196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer